Kadono, Y. (2021) “Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST”, Urology Journal, 19(03), pp. 202–208. doi: 10.22037/uj.v19i03.6652.